Rufinamide

Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome[1][2][3].

Product Specifications

CAS Number

[106308-44-5]

Product Name Alternative

CGP 33101; E 2080; RUF 331

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/rufinamide.html

Purity

99.84

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=CN(CC2=C(F)C=CC=C2F)N=N1)N

Molecular Formula

C10H8F2N4O

Molecular Weight

238.19

Precautions

H302, H315, H319, H335

References & Citations

[1]Suter MR, et.al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118 (1) :160-72.|[2]White HS, et.al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49 (7) :1213-20.|[3]Chen JL, et al. Inhibition of resurgent Na+ currents by rufinamide. Neuropharmacology. 2024 Apr 1;247:109835.